Production limitations put a damper on Novo Nordisk's potential growth
Novo Nordisk upgraded its full-year guidance on Friday last week, which raised the ambitions for its GLP-1 drugs in particular but the company’s growth has put a strain on its production.
by christopher due karlsson, translated by daniel pedersen
Danish pharmaceutical firm Novo Nordisk chose to publicize its first quarterly report for 2022 on Friday morning last week, which was a surprise for many, as it came half a week before schedule. The reason for this was a significant upgrade to the company’s expectations for 2022 sales and operating profit.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades full-year guidance
For subscribers
Novo Nordisk unveils Wegovy sales
For subscribers
